» Articles » PMID: 31007876

Exosomes from N-Myc Amplified Neuroblastoma Cells Induce Migration and Confer Chemoresistance to Non-N-Myc Amplified Cells: Implications of Intra-tumour Heterogeneity

Overview
Publisher Wiley
Date 2019 Apr 23
PMID 31007876
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastoma accounts for 15% of childhood cancer mortality. Amplification of the oncogene N-Myc is a well-established poor prognostic marker for neuroblastoma. Whilst N-Myc amplification status strongly correlates with higher tumour aggression and resistance to treatment, the role of N-Myc in the aggressiveness of the disease is poorly understood. Exosomes are released by many cell types including cancer cells and are implicated as key mediators in cell-cell communication via the transfer of molecular cargo. Hence, characterising the exosomal protein components from N-Myc amplified and non-amplified neuroblastoma cells will improve our understanding on their role in the progression of neuroblastoma. In this study, a comparative proteomic analysis of exosomes isolated from cells with varying N-Myc amplification status was performed. Label-free quantitative proteomic profiling revealed 968 proteins that are differentially abundant in exosomes released by the neuroblastoma cells. Gene ontology-based analysis highlighted the enrichment of proteins involved in cell communication and signal transduction in N-Myc amplified exosomes. Treatment of SH-SY5Y cells with N-Myc amplified SK-N-BE2 cell-derived exosomes increased the migratory potential, colony forming abilities and conferred resistance to doxorubicin induced apoptosis. Incubation of exosomes from N-Myc knocked down SK-N-BE2 cells abolished the transfer of resistance to doxorubicin induced apoptosis. These findings suggest that exosomes could play a pivotal role in N-Myc-driven aggressive neuroblastoma and transfer of chemoresistance between cells. : RNA = ribonucleic acid; DNA = deoxyribonucleic acid; FCS = foetal calf serum; NTA = nanoparticle tracking analysis; LC-MS = liquid chromatography-mass spectrometry; KD = knockdown; LTQ = linear trap quadropole; TEM = transmission electron microscopy.

Citing Articles

Exosomes in the Chemoresistance of Glioma: Key Point in Chemoresistance.

Guo X, Piao H, Sui R J Cell Mol Med. 2025; 29(4):e70401.

PMID: 39950738 PMC: 11826829. DOI: 10.1111/jcmm.70401.


Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.

Sharma R, Yadav J, Bhat S, Musayev A, Myrzagulova S, Sharma D Mol Neurobiol. 2025; .

PMID: 39804528 DOI: 10.1007/s12035-024-04680-w.


Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics.

Ren K, Wang Y, Zhang M, Tao T, Sun Z Children (Basel). 2024; 11(11).

PMID: 39594898 PMC: 11593200. DOI: 10.3390/children11111323.


Bioinformatics-Based Identification of Key Prognostic Genes in Neuroblastoma with a Focus on Immune Cell Infiltration and Diagnostic Potential of VGF.

Guo Q, Xiao Y, Chu J, Sun Y, Li S, Zhang S Pharmgenomics Pers Med. 2024; 17:453-472.

PMID: 39403102 PMC: 11472764. DOI: 10.2147/PGPM.S461072.


Extracellular Vesicles as Drug Delivery System for Cancer Therapy.

Wang J, Yin B, Lian J, Wang X Pharmaceutics. 2024; 16(8).

PMID: 39204374 PMC: 11359799. DOI: 10.3390/pharmaceutics16081029.


References
1.
McMahon G . VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000; 5 Suppl 1:3-10. DOI: 10.1634/theoncologist.5-suppl_1-3. View

2.
Adams J, Carder P, Downey S, FORBES M, MacLennan K, Allgar V . Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000; 60(11):2898-905. View

3.
Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

4.
Boubaker A, Bischof Delaloye A . Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med. 2003; 47(1):31-40. View

5.
Carmeliet P . VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69 Suppl 3:4-10. DOI: 10.1159/000088478. View